An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin ichiro Fujiwara, Mitsune Tanimoto

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

    Original languageEnglish
    Pages (from-to)409-412
    Number of pages4
    JournalActa medica Okayama
    Volume70
    Issue number5
    Publication statusPublished - Jan 1 2016

    Fingerprint

    Graft vs Host Disease
    Grafts
    Refractory materials
    Steroids
    Acute Promyelocytic Leukemia
    T-cells
    Cell Transplantation
    Tretinoin
    Cell Differentiation
    Cause of Death
    Down-Regulation
    Tissue Donors
    Morbidity
    T-Lymphocytes
    tamibarotene
    Therapeutics

    All Science Journal Classification (ASJC) codes

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Maeda, Y., Nishimori, H., Inamoto, Y., Nakamae, H., Sawa, M., Mori, Y., ... Tanimoto, M. (2016). An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. Acta medica Okayama, 70(5), 409-412.

    An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. / Maeda, Yoshinobu; Nishimori, Hisakazu; Inamoto, Yoshihiro; Nakamae, Hirohisa; Sawa, Masashi; Mori, Yasuo; Ohashi, Kazuteru; Fujiwara, Shin ichiro; Tanimoto, Mitsune.

    In: Acta medica Okayama, Vol. 70, No. 5, 01.01.2016, p. 409-412.

    Research output: Contribution to journalArticle

    Maeda, Y, Nishimori, H, Inamoto, Y, Nakamae, H, Sawa, M, Mori, Y, Ohashi, K, Fujiwara, SI & Tanimoto, M 2016, 'An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease', Acta medica Okayama, vol. 70, no. 5, pp. 409-412.
    Maeda, Yoshinobu ; Nishimori, Hisakazu ; Inamoto, Yoshihiro ; Nakamae, Hirohisa ; Sawa, Masashi ; Mori, Yasuo ; Ohashi, Kazuteru ; Fujiwara, Shin ichiro ; Tanimoto, Mitsune. / An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease. In: Acta medica Okayama. 2016 ; Vol. 70, No. 5. pp. 409-412.
    @article{31c5ca1216934c31b36e2c7870bc9c86,
    title = "An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease",
    abstract = "Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.",
    author = "Yoshinobu Maeda and Hisakazu Nishimori and Yoshihiro Inamoto and Hirohisa Nakamae and Masashi Sawa and Yasuo Mori and Kazuteru Ohashi and Fujiwara, {Shin ichiro} and Mitsune Tanimoto",
    year = "2016",
    month = "1",
    day = "1",
    language = "English",
    volume = "70",
    pages = "409--412",
    journal = "Acta Medica Okayama",
    issn = "0386-300X",
    publisher = "Okayama University",
    number = "5",

    }

    TY - JOUR

    T1 - An open-labeled, multicenter phase II study of tamibarotene in patients with steroid-refractory chronic graft-versus-host disease

    AU - Maeda, Yoshinobu

    AU - Nishimori, Hisakazu

    AU - Inamoto, Yoshihiro

    AU - Nakamae, Hirohisa

    AU - Sawa, Masashi

    AU - Mori, Yasuo

    AU - Ohashi, Kazuteru

    AU - Fujiwara, Shin ichiro

    AU - Tanimoto, Mitsune

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

    AB - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.

    UR - http://www.scopus.com/inward/record.url?scp=84997706142&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84997706142&partnerID=8YFLogxK

    M3 - Article

    C2 - 27777437

    AN - SCOPUS:84997706142

    VL - 70

    SP - 409

    EP - 412

    JO - Acta Medica Okayama

    JF - Acta Medica Okayama

    SN - 0386-300X

    IS - 5

    ER -